<DOC>
	<DOCNO>NCT01077271</DOCNO>
	<brief_summary>Compliance Synagis ( palivizumab ) key factor obtain maximal protection respiratory syncytial virus ( RSV ) infection show IMpact study . Many factor parent ' knowledge burden respiratory syncytial virus disease physician ' satisfaction Synagis well appropriate use product might influence compliance . The primary objective observational study evaluate compliance Synagis daily pediatricians practice condition premature infant 33 35 week gestational age ( wGA ) . Palivizumab , monoclonal antibody passive immunoprophylaxis severe respiratory syncytial virus disease , administer accord usual clinical practice . Compliance assess use four criterion : The number injection per participant per respiratory syncytial virus season , body site injection administer , interval day injection , dosage per administration . Originally study include two respiratory syncytial virus season extend third season .</brief_summary>
	<brief_title>Compliance Synagis ( Palivizumab ) Under Daily PediatricianÂ´s Conditions Premature Infants 33 - 35 wGA</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Premature infant 33 35 week gestational age Younger 3 month respiratory syncytial virus season start At least 4 point accord Austrian risk score accord Austrian guideline : 1 point young 3 month ( start respiratory syncytial virus season ) , 1 point neurologic disease , 1 point weight le 10th percentile , 1 point discharge hospital respiratory syncytial virus season ( 1 Oct 30 March ) , 1 point old sibling , 0.5 point multiple birth , 0.5 point day care attendance , 0.5 point passive tobacco smoke exposure , 0.5 point socioeconomic status ( overcrowd ) Synagis application ( prescription ) Signed authorization form data use ( parental authorization ) Patients without Synagis prescription Patients meet contraindication outline late version Synagis summary product characteristic ( SmPC ) : Patients know hypersensitivity palivizumab component formulation humanize monoclonal antibody Patients chronic lung disease Patients congenital heart disease Greater 36 week gestational age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Premature infant</keyword>
	<keyword>Respiratory Syncytial Virus ( RSV )</keyword>
	<keyword>Compliance</keyword>
	<keyword>Palivizumab</keyword>
</DOC>